The emerging role of interferon regulatory factor 9 in the antiviral host response and beyond

Cytokine and Growth Factor Reviews

Volumn 29, Issue , 2016, Pages 35-43

  Suprunenko, Tamara ^a   Hofer, Markus J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antiviral immunity; Interferon regulatory factor 9 (IRF9); Non canonical interferon signaling; Signal transducers and activators of transcription (STAT); Type I interferon signaling

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 7; INTERFERON REGULATORY FACTOR 9; PROTEIN KINASE R; STAT1 PROTEIN; STAT2 PROTEIN; IRF9 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN; STAT2 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; AUTOIMMUNITY; BINDING AFFINITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; IMMUNE RESPONSE; INSULIN SENSITIVITY; INTERFERON PRODUCTION; LIPID METABOLISM; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS CARCINOGENESIS; VIRUS INFECTION; ANIMAL; IMMUNOLOGY; PATHOLOGY;

ANIMALS; HUMANS; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; VIRUS DISEASES;

EID: 84960539978     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2016.03.002     Document Type: Short Survey

References (106)

1. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2013, 14:36-49.
2. Takaoka A., Yanai H. Interferon signalling network in innate defence. Cell. Microbiol. 2006, 8:907-922.
3. Galani I.E., Koltsida O., Andreakos E. Type III interferons (IFNs): emerging master regulators of immunity. Adv. Exp. Med. Biol. 2015, 850:1-15.
4. Gonzalez-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 2012, 12:125-135.
5. Pestka S., Krause C.D., Walter M.R. Interferons interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
6. Hofer M.J., Campbell I.L. Immunoinflammatory diseases of the central nervous system - the tale of two cytokines. Br. J. Pharmacol. 2015.
7. Nguyen H., Hiscott J., Pitha P.M. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 1997, 8:293-312.
8. Paun A., Pitha P.M. The IRF family, revisited. Biochim. 2007, 89:744-753.
9. Honda K., Taniguchi T. IRFs: master regulators of signalling by toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 2006, 6:644-658.
10. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 2001, 19:623-655.
11. Barnes B., Lubyova B., Pitha P.M. On the role of IRF in host defense. J. Interferon Cytokine Res. 2002, 22:59.
12. Levy D.E., Marie I., Smith E., Prakash A. Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J. Interferon Cytokine Res. 2002, 22:87-93.
13. Au W.C., Moore P.A., Lowther W., Juang Y.T., Pitha P.M. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:11657-11661.
14. Sato M., Tanaka N., Hata N., Oda E., Taniguchi T. Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. FEBS Lett. 1998, 425:112-116.
15. Marie I., Durbin J.E., Levy D.E. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 1998, 17:6660-6669.
16. Sato M., Hata N., Asagiri M., Nakaya T., Taniguchi T., Tanaka N. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 1998, 441:106-110.
17. Sato M., Suemori H., Hata N., Asagiri M., Ogasawara K., Nakao K., et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000, 13:539-548.
18. John J., McKendry R., Pellegrini S., Flavell D., Kerr I.M., Stark G.R. Isolation and characterization of a new mutant human cell line unresponsive to alpha and beta interferons. Mol. Cell. Biol. 1991, 11:4189-4195.
19. Kimura T., Kadokawa Y., Harada H., Matsumoto M., Sato M., Kashiwazaki Y., et al. Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1996, 1:115-124.
20. Hofer M.J., Li W., Lim S.L., Campbell I.L. The type I interferon-alpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9. J. Neurosci. 2010, 30:1149-1157.
21. Hofer M.J., Li W., Manders P., Terry R., Lim S.L., King N.J.C., et al. Mice deficient in STAT1 but not STAT2 or IRF9 develop a lethal CD4+ T-cell-mediated disease following infection with lymphocytic choriomeningitis virus. J. Virol. 2012, 86:6932-6946.
22. Harada H., Matsumoto M., Sato M., Kashiwazaki Y., Kimura T., Kitagawa M., et al. Regulation of IFN-alpha/beta genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN-alpha/beta. Genes Cells 1996, 1:995.
23. Au W.C., Raj N.B., Pine R., Pitha P.M. Distinct activation of murine interferon-alpha promoter region by IRF-1/ISFG-2 and virus infection. Nucleic Acids Res. 1992, 20:2877-2884.
24. Kirchhoff S., Koromilas A.E., Schaper F., Grashoff M., Sonenberg N., Hauser H. IRF-1 induced cell growth inhibition and interferon induction requires the activity of the protein kinase PKR. Oncogene 1995, 11:439-445.
25. Reis L.F., Harada H., Wolchok J.D., Taniguchi T., Vilcek J. Critical role of a common transcription factor, IRF-1, in the regulation of IFN-beta and IFN-inducible genes. EMBO J. 1992, 11:185-193.
26. Kroger A., Koster M., Schroeder K., Hauser H., Mueller P.P. Activities of IRF-1. J. Interferon Cytokine Res. 2002, 22:5-14.
27. Matsuyama T., Kimura T., Kitagawa M., Pfeffer K., Kawakami T., Watanabe N., et al. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 1993, 75:83-97.
28. Harada H., Willison K., Sakakibara J., Miyamoto M., Fujita T., Taniguchi T. Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell 1990, 63:303-312.
29. Ren G., Cui K., Zhang Z., Zhao K. Division of labor between IRF1 and IRF2 in regulating different stages of transcriptional activation in cellular antiviral activities. Cell Biosci. 2015, 5:17.
30. Barnes B.J., Moore P.A., Pitha P.M. Virus-specific activation of a novel interferon regulatory factor IRF-5, results in the induction of distinct interferon alpha genes. J. Biol. Chem. 2001, 276:23382-23390.
31. Takaoka A., Yanai H., Kondo S., Duncan G., Negishi H., Mizutani T., et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005, 434:243-249.
32. Sato M., Taniguchi T., Tanaka N. The interferon system and interferon regulatory factor transcription factors-studies from gene knockout mice. Cytokine Growth Factor Rev. 2001, 12:133-142.
33. Lohoff M., Duncan G.S., Ferrick D., Mittrucker H.W., Bischof S., Prechtl S., et al. Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J. Exp. Med. 2000, 192:325-336.
34. Kessler D.S., Veals S.A., Fu X.Y., Levy D.E. Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev. 1990, 4:1753.
35. Veals S.A., Schindler C., Leonard D., Fu X.Y., Aebersold R., Darnell J.J.E., et al. Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol. Cell. Biol. 1992, 12:3315-3324.
36. IRF9 Gene -GeneCards. (accessed 20 February, 2016). http://www.genecards.org/cgi-bin/carddisp.pl%3Fgene=irf9.
37. Genevisible-Top 10 tissues for Q61179, (accessed 20 February, 2016). http://genevisible.com/tissues/MM/UniProt/Q61179.
38. Dale T.C., Imam A.M., Kerr I.M., Stark G.R. Rapid activation by interferon alpha of a latent DNA-binding protein present in the cytoplasm of untreated cells. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:1203-1207.
39. Levy D.E., Kessler D.S., Pine R., Reich N., Darnell J.E. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev. 1988, 2:383-393.
40. Sarkis P.T., Ying S., Xu R., Yu X.F. STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J. Immunol. 2006, 177:4530-4540.
41. Levy D.E., Lew D.J., Decker T., Kessler D.S., Darnell J.E. Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J. 1990, 9:1105-1111.
42. Weihua X., Lindner D.J., Kalvakolanu D.V. The interferon-inducible murine p48 (ISGF3γ) gene is regulated by protooncogene c-myc. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7227-7232.
43. Dupuis S., Dargemont C., Fieschi C., Thomassin N., Rosenzweig S., Harris J., et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001, 293:300-303.
44. Picard C., Casanova J.-L. Inherited disorders of IFN-γ-, IFN-α/β-, and NF-κB-mediated immunity. Clinical Immunology: Principles and Practice 2008, 553-560. Elsevier/Saunders. 3rd edition. R.R. Rich, T.A. Fleisher, W.T. Shearer, H.W. Schroeder, A.J. Frew, C.M. Weyand (Eds.).
45. Fu X.Y., Kessler D.S., Veals S.A., Levy D.E., Darnell J.E. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:8555-8559.
46. Levy D.E., Kessler D.S., Pine R., Darnell J.E. Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro. Genes Dev. 1989, 3:1362-1371.
47. Lau J.F., Parisien J.P., Horvath C.M. Interferon regulatory factor subcellular localization is determined by a bipartite nuclear localization signal in the DNA-binding domain and interaction with cytoplasmic retention factors. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:7278-7283.
48. Banninger G., Reich N.C. STAT2 nuclear trafficking. J. Biol. Chem. 2004, 279:39199-39206.
49. Qureshi S.A., Salditt-Georgieff M., Darnell J.E. Tyrosine-phosphorylated Stat1 and Stat2 plus a 48-kDa protein all contact DNA in forming interferon-stimulated-gene factor 3. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3829-3833.
50. Veals S.A., Santa Maria T., Levy D.E. Two domains of ISGF3 gamma that mediate protein-DNA and protein-protein interactions during transcription factor assembly contribute to DNA-binding specificity. Mol. Cell. Biol. 1993, 13:196-206.
51. Bluyssen H.A.R., Durbin J.E., Levy D.E. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev. 1996, 7:11-17.
52. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
53. Kessler D.S., Levy D.E., Darnell J.E. Two interferon-induced nuclear factors bind a single promoter element in interferon-stimulated genes. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:8521-8525.
54. Bluyssen H.A.R., Levy D.E. Stat2 Is a transcriptional activator that requires sequence-specific contacts provided by stat1 and p48 for stable interaction with DNA. J. Biol. Chem 1997, 272:4600-4605.
55. Qureshi S.A., Leung S., Kerr I.M., Stark G.R., Darnell J.E. Function of Stat2 protein in transcriptional activation by alpha interferon. Mol. Cell. Biol. 1996, 16:288-293.
56. Kraus T.A., Lau J.F., Parisien J.P., Horvath C.M. A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response. J. Biol. Chem. 2003, 278:13033-13038.
57. Wesoly J., Szweykowska-Kulinska Z., Bluyssen H.A. STAT activation and differential complex formation dictate selectivity of interferon responses. Acta Biochim. Pol. 2007, 54:27-38.
58. Thibault D.L., Chu A.D., Graham K.L., Balboni I., Lee L.Y., Kohlmoos C., et al. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J. Clin. Invest. 2008, 118:1417-1426.
59. Thibault D.L., Graham K.L., Lee L.Y., Balboni I., Hertzog P.J., Utz P.J. Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res. Ther. 2009, 11:R112.
60. Oliver-Martos B., Orpez T., Pinto-Medel M.J., Mayorga C., Garcia-Leon J.A., Maldonado-Sanchez R., et al. Gene expression in IFNss signalling pathway differs between monocytes, CD4 and CD8T cells from MS patients. J. Neuroimmunol. 2011, 230:153-159.
61. Maier J., Kincaid C., Pagenstecher A., Campbell I.L. Regulation of signal transducer and activator of transcription and suppressor of cytokine-signaling gene expression in the brain of mice with astrocyte-targeted production of interleukin-12 or experimental autoimmune encephalomyelitis. Am. J. Pathol. 2002, 160:271-288.
62. Li X., Leung S., Qureshi S., Darnell J.E., Stark G.R. Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha. J. Biol. Chem. 1996, 271:5790-5794.
63. Shuai K., Stark G.R., Kerr I.M., Darnell J.E. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993, 261:1744-1746.
64. Fink K., Grandvaux N. STAT2 and IRF9: beyond ISGF3. Jak-Stat 2013, 2:e27521.
65. Campbell I.L., Krucker T., Steffensen S., Akwa Y., Powell H.C., Lane T., et al. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res. 1999, 835:46-61.
66. Ghislain J.J., Wong T., Nguyen M., Fish E.N. The interferon-inducible Stat2:Stat1 heterodimer preferentially binds in vitro to a consensus element found in the promoters of a subset of interferon-stimulated genes. J. Interferon Cytokine Res. 2001, 21:379-388.
67. Lou Y.J., Pan X.R., Jia P.M., Li D., Xiao S., Zhang Z.L., et al. IRF-9/STAT2 [corrected] functional interaction drives retinoic acid-induced gene G expression independently of STAT1. Cancer Res. 2009, 69:3673-3680.
68. Perry S.T., Buck M.D., Lada S.M., Schindler C., Shresta S. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog. 2011, 7:e1001297.
69. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 2008, 89:1-47.
70. Gupta S., Jiang M., Pernis A.B. IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. J. Immunol. 1999, 163:3834-3841.
71. Matsumoto M., Tanaka N., Harada H., Kimura T., Yokochi T., Kitagawa M., et al. Activation of the transcription factor ISGF3 by interferon-gamma. Biol. Chem. 1999, 380:699-703.
72. Morrow A.N., Schmeisser H., Tsuno T., Zoon K.C. A novel role for IFN-stimulated gene factor 3II in IFN-gamma signaling and induction of antiviral activity in human cells. J. Immunol. 2011, 186:1685-1693.
73. Bluyssen H.A.R., Muzaffar R., Vlieststra R.J., Leung S., Stark G.R., Kerr I.M., et al. Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5645-5649.
74. Rauch I., Rosebrock F., Hainzl E., Heider S., Majoros A., Wienerroither S., et al. Noncanonical effects of IRF9 in intestinal inflammation: more than type I and type III interferons. Mol. Cell. Biol. 2015, 35:2332-2343.
75. Groom J.R., Luster A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 2011, 89:207-215.
76. Mahlakõiv T., Hernandez P., Gronke K., Diefenbach A., Staeheli P. Leukocyte-derived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 2015, 11:e1004782.
77. Mordstein M., Neugebauer E., Ditt V., Jessen B., Rieger T., Falcone V., et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 2010, 84:5670-5677.
78. Thompson C.L., Hofer M.J., Campbell I.L., Holmes A.J. Community dynamics in the mouse gut microbiota: a possible role for IRF9-regulated genes in community homeostasis. PLoS One 2010, 5:e10335.
79. Wang X.A., Zhang R., Jiang D., Deng W., Zhang S., Deng S., et al. Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology 2013, 58:603-616.
80. van Raalte D.H., Li M., Pritchard P.H., Wasan K.M. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm. Res. 2004, 21:1531-1538.
81. Zhang Y., Liu X., She Z.G., Jiang D.S., Wan N., Xia H., et al. Interferon regulatory factor 9 is an essential mediator of heart dysfunction and cell death following myocardial ischemia/reperfusion injury. Basic Res. Cardiol. 2014, 109:434.
82. Chen H.Z., Guo S., Li Z.Z., Lu Y., Jiang D.S., Zhang R., et al. A critical role for interferon regulatory factor 9 in cerebral ischemic stroke. J. Neurosci. 2014, 34:11897-11912.
83. Wang P.X., Zhang R., Huang L., Zhu L.H., Jiang D.S., Chen H.Z., et al. Interferon regulatory factor 9 is a key mediator of hepatic ischemia/reperfusion injury. J. Hepatol. 2015, 62:111-120.
84. Zhang S.M., Zhu L.H., Chen H.Z., Zhang R., Zhang P., Jiang D.S., et al. Interferon regulatory factor 9 is critical for neointima formation following vascular injury. Nat. Commun. 2014, 5:5160.
85. Jiang D.S., Luo Y.X., Zhang R., Zhang X.D., Chen H.Z., Zhang Y., et al. Interferon regulatory factor 9 protects against cardiac hypertrophy by targeting myocardin. Hypertension 2014, 63:119-127.
86. Tamura T., Yanai H., Savitsky D., Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 2008, 26:535-584.
87. Savitsky D., Tamura T., Yanai H., Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol. Immunother. 2010, 59:489-510.
88. Takaoka A., Honda K., Taniguchi T., Hayakawa S., Yanai H., Stoiber D., et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424:516.
89. Tsuno T., Mejido J., Zhao T., Schmeisser H., Morrow A., Zoon K.C. IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha. J. Immunother. 2009, 32:803-816.
90. Wu W.Z., Sun H.C., Gao Y.Q., Li Y., Wang L., Zhou K., et al. Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells. Oncology 2004, 67:428-440.
91. Matin S.F., Rackley R.R., Sadhukhan P.C., Kim M.S., Novick A.C., Bandyopadhyay S.K. Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res. 2001, 61:2261-2266.
92. Xu B., Grander D., Sangfelt O., Einhorn S. Primary leukemia cells resistant to alpha-interferon in vitro are defective in the activation of the DNA-binding factor interferon-stimulated gene factor 3. Blood 1994, 84:1942-1949.
93. Wong L.H., Krauer K.G., Hatzinisiriou I., Estcourt M.J., Hersey P., Tam N.D., et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1 STAT2, and p48-ISGF3gamma. J. Biol. Chem. 1997, 272:28779-28785.
94. Gough D.J., Messina N.L., Clarke C.J., Johnstone R.W., Levy D.E. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012, 36:166-174.
95. Barnard P., McMillan N.A. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999, 259:305-313.
96. Leonard G.T., Sen G.C. Effects of adenovirus E1A protein on interferon-signaling. Virology 1996, 224:25-33.
97. Leonard G.T., Sen G.C. Restoration of interferon responses of adenovirus E1A-expressing HT1080 cell lines by overexpression of p48 protein. J. Virol. 1997, 71:5095-5101.
98. Miller D.M., Zhang Y., Rahill B.M., Waldman W.J., Sedmak D.D. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J. Immunol. 1999, 162:6107-6113.
99. Miller D.M., Cebulla C.M., Sedmak D.D. Human cytomegalovirus inhibition of major histocompatibility complex transcription and interferon signal transduction. Curr. Top. Microbiol. Immunol. 2002, 269:153-170.
100. Paulus C., Krauss S., Nevels M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3840-3845.
101. Gibbert K., Schlaak J.F., Yang D., Dittmer U. IFN-alpha subtypes: distinct biological activities in anti-viral therapy. Br. J. Pharmacol. 2013, 168:1048-1058.
102. Javed A., Reder A.T. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol. Ther. 2006, 110:35-56.
103. Razonable R.R. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin. Proc. 2011, 86:1009-1026.
104. Wang B.X., Rahbar R., Fish E.N. Interferon: current status and future prospects in cancer therapy. J. Interferon Cytokine Res. 2011, 31:545-552.
105. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997, 26:112s-121s.
106. Schreiber G., Piehler J. The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol. 2015, 36:139-149.